Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00878995 · ClinicalTrials.gov registry record · Phase 1
Testosterone for Treating Cachexia in Patients With Squamous Cell Carcinoma
A Phase 1 study, sponsored by The University of Texas Medical Branch, Galveston.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT00878995 is a Phase 1 study that has completed, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 28 participants.
The verdict
NCT00878995, a Phase 1 study, has completed, sponsored by The University of Texas Medical Branch, Galveston.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
RATIONALE: Testosterone may lessen weight loss and improve muscle size and strength in patients with cachexia caused by cancer. PURPOSE: This randomized phase I trial is studying whether testosterone administered during standard of care chemotherapy and/or radiation works by helping patients with squamous cell carcinoma to maintain their body weight and muscle size and strength during treatment.
Interventions
- DRUG Placebo Testosterone
- DRUG Testosterone Enanthate 100 MG/ML
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2009-06-03 |
| Est. Completion | 2015-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00878995
The ClinicalTrials.gov registry entry for NCT00878995 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Medical Branch, Galveston, which has 203 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Testosterone is the first listed.
NCT00878995 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00878995 about?
NCT00878995 is a clinical study titled "Testosterone for Treating Cachexia in Patients With Squamous Cell Carcinoma". RATIONALE: Testosterone may lessen weight loss and improve muscle size and strength in patients with cachexia caused by cancer. PURPOSE: This randomized phase I trial is studying whether testosterone administered during standard of care chemotherapy and/or radiation works by helping patients with s...
What is the current status of trial NCT00878995?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2009-06-03. Estimated completion is 2015-06.
What interventions are being tested in trial NCT00878995?
The interventions under investigation include: Placebo Testosterone (DRUG), Testosterone Enanthate 100 MG/ML (DRUG).
Who is sponsoring clinical trial NCT00878995?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.